A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive breast cancer.

Trial Details

NCT ID
NCT06747338
Phase
PHASE3
Sponsor
Shanghai JMT-Bio Inc.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • KN026
  • HB1801
  • Pertuzumab
  • Trastuzumab
  • Docetaxel
  • Carboplatin
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntarily participate in the experiment and sign the informed consent;
  • Aged \>= 18 years;
  • Histologically and cytologically confirmed primary invasive carcinoma of the breast with early (T2-3, N0-1, M0) or locally advanced stage (T2-3, N2…
  • ECOG PS 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →